Katherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.
Katherine Tkaczuk, MD
Advertisement
Articles by Katherine Tkaczuk, MD
Advertisement
Latest Updated Articles
Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast CancerPublished: October 5th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
The OncFive: Top Oncology Articles for the Week of 1/25
4
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
5